POLARYX THERAPEUTICS INC
PLYXNASDAQ🏆 #3046 by market capUS Equity
$202.89▼ $7.93 (−3.91%)
Simulated price1h—
24h▼ 3.9%
7d—
14d—
30d—
1y—
🏦Market Cap
$114M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
47
Weak
No chart data available for PLYX.
Trading Snapshot
- Day Range
- $201.99 – $206.06
- 52-Week Range
- $2.01 – $48.91
- Volume
- $2.12B
- Avg Volume
- $1.44B
- Shares Outstanding
- 49.9M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.08
- Dividend Yield
- —
Why Investors Own PLYX
- ✓High-growth profile — revenue up -2.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 46% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$12M▼ −5.5% YoY
Gross Margin (TTM)
46.2%▲ +1.9% YoY
Operating Income (TTM)
$4M▼ −5.5% YoY
Free Cash Flow (TTM)
$576,368▼ −5.5% YoY
About POLARYX THERAPEUTICS INC
A company profile for POLARYX THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
47/100
Analyst Price Target
ⓘAverage Target
$236.77
▲ +16.7% Upside
High Target$291.88
Low Target$221.59
Based on 23 analysts
Latest News & Updates
🚀
CNBC·2h ago
POLARYX THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift PLYX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
POLARYX THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.